The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx files to sell 8.44M shares of common stock for holders
- RenovoRx: Building Commercial Momentum Ahead of TIGeR-PaC Readout Supports Buy-Rated Risk‑Reward Profile
- RenovoRx secures Japanese patent allowance for targeted drug-delivery
- RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial
- RNXT Upcoming Earnings Report: What to Expect?